Claims
- 1. A compound having the following formula (I) ##STR34## wherein n and n.sub.1 are, independently, 1, 2 or 3;
- one or more of the groups R and R.sub.1, which may be the same or different, is --NO.sub.2 or ##STR35## wherein R.sub.5 and R.sub.6 are, independently, hydrogen or C.sub.1 -C.sub.6 alkyl, or two adjacent R groups or two adjacent R.sub.1 groups, taken together, form the --O--CH.sub.2 --O-- radical; and the remainder of the groups R and R.sub.1 are hydrogen;
- R.sub.3 is (a') hydrogen; (b') C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by one or more substituents chosen from the group consisting of halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, ##STR36## where R.sub.5 and R.sub.6 are as defined above; (c') C.sub.2 -C.sub.4 alkenyl; C.sub.2 -C.sub.4 alkynyl; (d') phenyl-C.sub.1 -C.sub.4 alkyl, in which the phenyl group may be unsubstituted or substituted by one or more substituents chosen from the group consisting of C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy, and ##STR37## wherein R.sub.5 and R.sub.6 are as defined above; (e') C.sub.3 -C.sub.7 cycloalkyl unsubstituted or substituted by one or more C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -Chd 6 alkoxy and ##STR38## where R.sub.5 and R.sub.6 are as defined above; and the pharmaceutically acceptable salts thereof.
- 2. A compound having the following formula (I) ##STR39## wherein n and n.sub.1 are, indpendently, 1, 2 or 3;
- two adjacent R groups or two adjacent R.sub.1 groups, taken together, form the --O--CH.sub.2 --O-- radical, and the other groups R and R.sub.1 are hydrogen; R.sub.3 is (a') hydrogen; (b') C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by one or more substituents chosen from the group consisting of halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, ##STR40## where R.sub.5 and R.sub.6 are as defined above; (c') C.sub.2 -C.sub.4 alkenyl; C.sub.2 -C.sub.4 alkynyl; (d') phenyl-C.sub.1 -C.sub.4 alkyl, in which the phenyl group may be unsubstituted or substituted by one or more substituents chosen from the group consisting of C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy, and ##STR41## where R.sub.5 and R.sub.6 are as defined above; (e') C.sub.3 -C.sub.7 cycloalkyl unsubstituted or substituted by one or more C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy and ##STR42## where R.sub.5 and R.sub.6 are as defined above; and the pharmaceutically acceptable salts thereof.
- 3. A compound having the following formula (I) ##STR43## wherein n and n.sub.1 are, independently, 1, 2 or 3;
- two adjacent R groups or two adjacent R.sub.1 groups, taken together, form the --O--CH.sub.2 --O-- radical, and the other groups R and R.sub.1 are hydrogen;
- R.sub.3 is hydrogen, methyl or isopropyl;
- and the pharmaceutically acceptable salts thereof.
- 4. 2-[.alpha.-(3,4-methylendioxy-phenoxy)-benzyl]-morpholine and the pharmaceutically acceptable salts thereof.
- 5. A salt of the compound of claim 3 wherein the salt is the hydrochloride.
- 6. A compound having the following formula (I) ##STR44## wherein n and n.sub.1 are, independently, 1, 2 or 3;
- one or more of the groups R and R.sub.1, which may be the same or different, is --NO.sub.2 or ##STR45## wherein R.sub.5 and R.sub.6 are, independently, hydrogen or C.sub.1 -C.sub.6 alkyl, and the remainder of the groups R and R.sub.1 are hydrogen; R.sub.3 is (a') hydrogen; (b') C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by one or more substituents chosen from the group consisting of halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, ##STR46## where R.sub.5 and R.sub.6 are as defined above; (c') C.sub.2 -C.sub.4 alkenyl; C.sub.2 -C.sub.4 alkynyl; (d') phenyl-C.sub.1 -C.sub.4 alkyl, in which the phenyl group may be unsubstituted or substituted by one or more substituents chosen from the group consisting of C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy, and ##STR47## where R.sub.5 and R.sub.6 are as defined above; (e') C.sub.3 -C.sub.7 cycloalkyl unsubstituted or substituted by one or more C.sub.1 -C.sub.6 alkyl, halogen, halo-C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy and ##STR48## where R.sub.5 and R.sub.6 are as defined above; and the pharmaceutically acceptable salts thereof.
- 7. A compound selected from the group consisting of:
- 2-[.alpha.-(2-N,N-dimethylamino-phenoxy)-benzyl]-4-methyl-morpholine;
- 2-[.alpha.-(2-amino-phenoxy)-benzyl]-4-methyl-morpholine;
- 2-[.alpha.-(2-nitro-phenoxy)-benzyl]-morpholine,
- and the pharmaceutically acceptable salts thereof.
- 8. An antidepressant composition comprising an antidepressant effective amount of a compound according to any one of claims 1-7 and a pharmaceutically acceptable carrier and/or diluent.
Priority Claims (5)
Number |
Date |
Country |
Kind |
19449 A/78 |
Jan 1978 |
ITX |
|
19450 A/78 |
Jan 1978 |
ITX |
|
30533 A/78 |
Dec 1978 |
ITX |
|
30534 A/78 |
Dec 1978 |
ITX |
|
30535 A/78 |
Dec 1978 |
ITX |
|
Parent Case Info
This is a divisional application of Ser. No. 1,604, filed Jan. 8, 1979 now U.S. Pat. No. 4,229,449.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3974158 |
Young |
Aug 1976 |
|
4016284 |
Vanhoof et al. |
Apr 1977 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
1604 |
|
|